## Cardiac Output Reduction in Heart Failure with Reduced Ejection Fraction (HFrEF) ### Clinical Context This patient presents with **systolic heart failure** (HFrEF) characterized by: - Reduced ejection fraction (EF = 35%, normal >50%) - Elevated LVEDP (22 mmHg, normal <12 mmHg) → indicates impaired diastolic relaxation and elevated filling pressures - Left ventricular hypertrophy (LVH) from chronic hypertension - Elevated JVP → right ventricular dysfunction and elevated right atrial pressure - Dyspnea on exertion → pulmonary congestion from elevated LV filling pressures ### Pathophysiology of Reduced Cardiac Output **Key Point:** In HFrEF, cardiac output is reduced due to TWO primary mechanisms: 1. **Reduced Contractility (Systolic Dysfunction)** - Myocardial dysfunction from chronic hypertension, prior MI, or idiopathic cardiomyopathy - Loss of contractile force → reduced ability to eject blood - Ejection fraction = (SV / LVEDV) is reduced - Result: Decreased stroke volume 2. **Increased Afterload (Elevated Systemic Vascular Resistance)** - Chronic hypertension causes sustained elevation in SVR - In HF, sympathetic activation further increases SVR via α-adrenergic vasoconstriction - Increased afterload opposes ventricular ejection → further reduces SV - Elevated LVEDP reflects the ventricle's inability to eject against high afterload ### Compensatory Mechanisms (Neurohormonal Activation) The body attempts to maintain CO through: - **Sympathetic activation** → increased HR (tachycardia) and contractility (via β₁ receptors) - **RAAS activation** → fluid retention to increase preload (Frank-Starling mechanism) - **Vasopressin release** → further fluid retention **Clinical Pearl:** These compensatory mechanisms are initially beneficial (maintaining CO) but become maladaptive long-term, leading to: - Progressive fluid overload (pulmonary and systemic edema) - Further increase in afterload (vicious cycle) - Worsening myocardial dysfunction ### Why Option 2 is Correct Option 2 accurately identifies: 1. **Reduced contractility** → primary cause of reduced SV in HFrEF 2. **Increased afterload** → from chronic hypertension and sympathetic activation, further limiting SV 3. **Compensatory sympathetic activation** → attempting to maintain CO but ultimately worsening the condition This is the most complete and mechanistically accurate description of HFrEF pathophysiology. **High-Yield:** The elevated LVEDP (22 mmHg) is a key finding indicating that the ventricle must generate higher filling pressures to achieve any stroke volume — this is the hallmark of systolic dysfunction with impaired contractility. ## Comparison: Mechanisms of Reduced CO in Different HF Types | Mechanism | HFrEF (Systolic) | HFpEF (Diastolic) | This Patient | |-----------|------------------|-------------------|---------------| | Contractility | ↓↓ (primary) | Normal | ↓↓ | | Afterload | ↑ (secondary) | ↑ (primary) | ↑↑ | | Preload | ↑ (compensatory) | ↑ (primary) | ↑ | | LVEDP | ↑ (elevated) | ↑↑ (very elevated) | ↑ (22 mmHg) | | EF | <40% | >50% | 35% | | Main problem | Weak pump | Stiff ventricle | Weak pump + high resistance | ### Why Other Options Are Incorrect | Option | Issue | |--------|-------| | Option 0 | While sympathetic activation does occur, the statement that it "leads to tachycardia and increased afterload that further reduces cardiac output" is misleading. Sympathetic activation is a COMPENSATORY mechanism; the primary problem is reduced contractility and elevated afterload from hypertension. This option reverses cause and effect. | | Option 1 | Incorrect: Preload is INCREASED in HFrEF (not decreased), as evidenced by elevated LVEDP and JVP. Pulmonary edema develops due to elevated filling pressures, not reduced preload. This is a fundamental misunderstanding. | | Option 3 | Completely incorrect: Parasympathetic tone is typically DECREASED in HF, not increased. The patient has a normal resting HR (88 bpm), not bradycardia. Parasympathetic withdrawal is part of the sympathetic dominance in HF. | **Mnemonic:** **REACH** for HFrEF — **R**educed contractility, **E**levated afterload, **A**ctivated sympathetic system, **C**ompensatory mechanisms (fluid retention), **H**igh LVEDP = Reduced cardiac output ## Clinical Management Implications Treatment targets the two primary problems: 1. **Improve contractility:** ACE inhibitors, β-blockers, inotropes (dobutamine, milrinone) 2. **Reduce afterload:** ACE inhibitors, ARBs, hydralazine, nitrates 3. **Reduce preload:** Diuretics, fluid restriction 4. **Block neurohormonal activation:** β-blockers, ACE inhibitors, aldosterone antagonists
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.